Participated · Series B · Mar 2026

Greater Good Health partners with health plans, hospital systems, and provider groups to offer nurse practitioner–led primary care clinics and embedded clinical programs that lower total cost of care while improving quality and access. The company currently serves more than 200,000 patients through its clinics and integrated services platform, achieving 4-plus STAR quality scores, over 200 % growth in preventive-care engagement, reduced unnecessary acute admissions, and a Net Promoter Score above 90. Its first three clinics launched in Montana with Humana, and a fourth clinic opened in Idaho with Blue Cross of Idaho, highlighting the model’s scalability in underserved, aging markets. Based in El Segundo, California, Greater Good Health focuses on Medicare adults and addresses the national shortage of primary care physicians by elevating nurse practitioners to lead care teams. The organization functions as an extension of risk-bearing entities, supplying the infrastructure and staffing needed for longitudinal, value-based care management. With fresh capital, the company plans to deepen payer partnerships, strengthen its technology-enabled care platform, and expand into additional geographies.

Participated · Equity · Mar 2026

KeyCare is a Chicago-based national virtual care organization built on the Epic electronic health record platform. Its technology integrates directly into existing clinical workflows and data infrastructure, enabling health systems to offer virtual visits that are coordinated with in-person care. By embedding into Epic, KeyCare helps providers maintain continuity of records, scheduling, and billing while giving patients a seamless telehealth experience. The company focuses on improving patient and clinician satisfaction through streamlined virtual encounters and robust data sharing. With new capital, KeyCare plans to deepen its investment in AI-enabled capabilities, enhance its platform features, and scale operational capacity to meet rising demand from health-system partners. To date, the company has raised more than $55 million.

Participated · Series A · Feb 2026

Daffodil Health provides an AI-first, configurable platform that overlays existing claims systems to automate repricing, payment integrity, and real-time claims support for health insurers and third-party administrators. Its transparent benchmarks and pricing logic help payers adopt modern plan designs such as reference-based pricing, narrow or tiered networks, and dynamic copays while avoiding percentage-of-savings middlemen. The company charges a predictable SaaS fee, aligning incentives and enabling faster deployment than legacy vendors. Across current deployments, Daffodil has generated consistent seven-figure margin improvements; one payer saved roughly $4 million in vendor fees during the first year alone. The fresh capital will accelerate product development and broaden market penetration. Headquartered in San Francisco, Daffodil has raised $20.9 million to date, positioning it to scale its payment integrity solution amid rising demand for price transparency and auditability in healthcare.

Led · Series B · Dec 2025

Reema Health partners with health plans to reduce total cost of care, boost revenue, and increase effective healthcare utilization among difficult-to-reach members. Its model combines community-based "guides" who live in the neighborhoods they serve with proprietary technology, predictive analytics, and algorithms that pinpoint high-risk, high-cost individuals most likely to benefit from preventive services. The platform directs guides to deliver in-person, high-touch support while scaling engagement capacity through precision outreach tools. Over the past year, Reema Health expanded operations from four to 14 markets and plans launches in three additional states in early 2026. The company is also broadening its program portfolio to include maternal health and other offerings tailored to Medicaid Managed Care Organizations and health plans. These efforts aim to maintain meaningful member connections while demonstrating measurable return on investment. Financial details beyond funding were not disclosed, but the firm’s rapid geographic growth underscores strong market traction.

Participated · Series B · Nov 2025

House Rx is a San Francisco–based health technology company redesigning specialty pharmacy by embedding locally owned dispensaries inside specialty clinics, shifting control away from traditional PBM-centric models. Its proprietary pharmacy management platform uses embedded AI workflows—such as the new “Smart PA” feature that automates up to 80 % of prior authorizations—to streamline operations and accelerate treatment starts. The company partners with more than 1,000 providers across 80 clinic sites nationwide and currently processes about $1.5 billion in specialty prescriptions annually, a figure it expects to double to $3 billion by 2026. By colocating pharmacists with physicians, House Rx aims to boost patient adherence, cut costs, and deliver high-touch care for complex conditions. Recent funding will allow the company to expand its in-clinic model to additional medical specialties and continue building AI-native capabilities. Management intends to scale operations rapidly to meet growing demand from providers, manufacturers, and payers. Total capital raised now stands at $100 million, providing resources for both geographic and technological expansion.